Comparative Analysis of Copeptin, IL-6, and TNF-α as Predictive Biomarkers for Clinical Outcome in Moderate to Severe COVID-19 Patients
DOI:
https://doi.org/10.36497/jri.v46i1.1114Keywords:
copeptin, COVID-19, IL-6, SARS-CoV-2, TNF-αAbstract
Background: Cytokine release syndrome (CRS) plays a central role in disease progression, driven by pro-inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), as well as neuroendocrine stress markers such as copeptin. Perbandingan langsung biomarker copeptin, IL-6, dan TNF-α sangat penting untuk mengidentifikasi prediktor hasil COVID-19 yang paling andal, terutama pada kasus sedang hingga berat. This retrospective clinical study aimed to evaluate the correlation of copeptin, IL-6, and TNF-α levels with the clinical outcomes of patients with moderate to severe COVID-19.
Methods: The study included patients who met the selection criteria and provided written informed consent. A sample size of 41 was determined via power analysis to achieve 80% power at a 0.05 significance level. Consecutive sampling was employed to select participants. The study utilized medical records of patients with moderate to severe COVID-19 who underwent copeptin, IL-6, and TNF-α testing. Correlation analyses and Bonferroni corrections were performed using SPSS® ver. 21.
Results: Results revealed a moderate positive correlation between copeptin levels and patient outcomes (Bonferroni correlation=0.597; P<0.001). A weak positive correlation was observed between IL-6 levels and outcomes (Bonferroni correlation=0.239; P=0.055), while a negligible positive correlation was found for TNF-α levels (Bonferroni correlation=0.140; P=0.177), which was not statistically significant.
Conclusion: Copeptin emerged as a more sensitive biomarker for predicting the outcomes of COVID-19 patients. Elevated copeptin levels were associated with a poorer prognosis. Furthermore, its stability in serum renders copeptin a more sensitive biomarker than IL-6 and TNF-α.
Downloads
References
1. Abdelmoaty MM, Yeapuri P, Machhi J, Olson KE, Shahjin F, Kumar V, et al. Defining the innate immune responses for SARS-CoV-2-Human macrophage interactions. Front Immunol. 2021;12:741502.
2. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020;117(17):9490–6.
3. Guan W jie, Ni Z yi, Hu Y, Liang W hua, Ou C quan, He J xing, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.
4. Li X, Raventós B, Roel E, Pistillo A, Martinez-Hernandez E, Delmestri A, et al. Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: Population based cohort and self-controlled case series analysis. BMJ. 2022;376:e068373.
5. Zawawi ZM, Kalyanasundram J, Mohd Zain R, Thayan R, Basri DF, Yap WB. Prospective roles of tumor necrosis factor-alpha (TNF-α) in COVID-19: Prognosis, therapeutic and management. Int J Mol Sci. 2023;24(7):6142.
6. Thermo Fisher Scientific. Human TNFα instant ELISA kit user guide. 2019.
7. Chen KY, Chang CY, Hsu HJ, Shih HJ, Huang IT, Patel HH, et al. Tumor necrosis factor-α mediates lung injury in the early phase of endotoxemia. Pharmaceuticals. 2022;15(3):287.
8. Reviono. Pneumonia: Adakah tempat untuk pemberian antinflamasi. 1st ed. Harsini, editor. Surakarta: UNS Press; 2017.
9. Du JM, Sang G, Jiang CM, He XJ, Han Y. Relationship between plasma copeptin levels and complications of community-acquired pneumonia in preschool children. Peptides (NY). 2013;45:61–5.
10. Hammad R, Elshafei A, Khidr EG, El-Husseiny AA, Gomaa MH, Kotb HG, et al. Copeptin: A neuroendocrine biomarker of COVID-19 severity. Biomark Med. 2022;16(8):589–97.
11. Azam M, Sulistiana R, Ratnawati M, Fibriana AI, Bahrudin U, Widyaningrum D, et al. Recurrent SARS-CoV-2 RNA positivity after COVID-19: A systematic review and meta-analysis. Sci Rep. 2020;10(1):20692.
12. Jalleh R, Torpy D. The emerging role of copeptin. Clinical Biochemist Reviews. 2021;42(1):17–25.
13. Oda G, Sharma A, Lucero-Obusan C, Schirmer P, Sohoni P, Holodniy M. COVID-19 infections among healthcare personnel in the United States Veterans Health Administration, March to August, 2020. J Occup Environ Med. 2021;63(4):291–5.
14. Shrestha RM, Inoue Y, Fukunaga A, Van Hoang D, Yamamoto S, Miki T, et al. Infection prevention practices and its associated factors among hospital workers in a national medical center designated for COVID-19 in Tokyo, Japan. PLoS One. 2022;17(8 August):e0272856.
15. Tan GM, Chi KWK, Yan BPY. Mid-term results of a novel dedicated venous stent for the treatment of chronic thoracic central vein obstruction of benign aetiology. Eur J Vasc Endovasc Surg. 2019;57(3):417–23.
16. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. The Lancet. 2020;395(10229):1054–62. PubMed PMID: 32171076.
17. Hadi C, Pramana C. Profile of covid-19 patients in dr. Moewardi hospital Surakarta Indonesia. Open Access Maced J Med Sci. 2021;9(B):1621–4.
18. Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine storm in COVID-19: The current evidence and treatment strategies. Front Immunol. 2020;11:1708.
19. Guo Y, Hu K, Li Y, Lu C, Ling K, Cai C, et al. Targeting TNF-α for COVID-19: Recent advanced and controversies. Front Public Health. 2022;10:833967.
20. Cheong KH, Ngiam NJ, Morgan GG, Pek PP, Tan BYQ, Lai JW, et al. Acute health impacts of the southeast asian transboundary haze problem - A review. Int J Environ Res Public Health. 2019;16(18):3286.
21. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141–54.
22. Al-Salam ASA, Esmaeel NA, AL-Ganimi AKA. Role of TNF-α in patients with omicron coronavirus: A cross-sectional study. Med J Babylon. 2024;20(4):766–70.
23. Jang DI, Lee AH, Shin HY, Song HR, Park JH, Kang TB, et al. The role of tumor necrosis factor alpha (Tnf-α) in autoimmune disease and current tnf-α inhibitors in therapeutics. Int J Mol Sci. 2021;22(5):2719.
24. Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm; What We know so far. Front Immunol. 2020;11:1446.
25. Kuluöztürk M, İn E, Telo S, Karabulut E, Geçkil AA. Efficacy of copeptin in distinguishing COVID-19 pneumonia from community-acquired pneumonia. J Med Virol. 2021;93(5):3113–21.
26. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: Consider cytokine storm syndromes and immunosuppression. The Lancet. 2020;395(10229):1033–4.
27. Roscioli E, Hamon R, Lester SE, Jersmann HPA, Reynolds PN, Hodge S. Airway epithelial cells exposed to wildfire smoke extract exhibit dysregulated autophagy and barrier dysfunction consistent with COPD. Respir Res. 2018;19(1):234.
28. Thermo Fisher Scientific Inc. Human Copeptin ELISA Kit Catalog Number EEL038 (96 tests) Rev 2.1. Vienna: Thermo Fisher Scientific Inc; 2025.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Harsini, Jatu Aphridasari, Sihsusetyaningtyas Tiominar Siregar
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
- The authors own the copyright of published articles. Nevertheless, Jurnal Respirologi Indonesia has the first-to-publish license for the publication material.
- Jurnal Respirologi Indonesia has the right to archive, change the format and republish published articles by presenting the authors’ names.
- Articles are published electronically for open access and online for educational, research, and archiving purposes. Jurnal Respirologi Indonesia is not responsible for any copyright issues that might emerge from using any article except for the previous three purposes.
